GENEVA, Aug. 12, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX:Â MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and DroiaProvides the company with capital needs through potential U.S. regulatory approval of engasertibMarks the company's transition into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib, a once daily oral medication, in patients with moderate-to-severe hereditary hemorrhagic telangiectasia (HHT)
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and DroiaProvides the company with capital needs through potential U.S. regulatory approval of engasertibMarks the company's transition into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib, a once daily oral medication, in patients with moderate-to-severe hereditary hemorrhagic telangiectasia (HHT)
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and DroiaProvides the company with capital needs through potential U.S. regulatory approval of engasertibMarks the company's transition into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib, a once daily oral medication, in patients with moderate-to-severe hereditary hemorrhagic telangiectasia (HHT)
Recognition Highlights Ontinue Strengths: Production-Validated Agentic Automation with Balanced Governance, Microsoft Investment Protection With European Data Sovereignty and Capacity-Based Engagement Model With Service Transparency
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026.
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICSÂ (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICSÂ (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /CNW/ -- SOPHiA GENETICSÂ (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
